A story in India's Economic Times makes an apples-to-oranges suggestion that India has agreed to supply generic cancer drugs to the U.S. "at a time there is outrage in America about the predatory practices by the U.S. pharma industry, one of whose leaders is getting hammered for increasing the price of life-saving drugs by as much as 5,000% overnight." However, the newspaper said, that while details were not available, Indian officials had confirmed that New Delhi had agreed to supply an "off-patent" cancer drug, presumably in response--even though the drug in question was not oncology-related. "Such a move could be a template for the supply of life-saving pharmaceuticals to a U.S. system that is overpriced and overburdened, causing untold suffering to millions of poor and middleclass Americans." The story did mention Martin Shkreli and his biotech, Turing Pharmaceuticals, who did jack up prices of the 62-year-old drug Daraprim, the standard treatment for the dangerous blood infection toxoplasmosis, from $13.50 a pill to $750, in a weekend move that drew worldwide rebuke. But moving from there to a pact between India and the U.S. on cancer drugs does seem a bit stretched. Report